The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 17: 2363 - 2368

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.17.002

Clinical Advances

Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma

  • Sishi XU ,
  • Peipei. YE
Expand
  • *.Health Science Center，Ningbo University，Ningbo 315211，China

Received date: 2024-02-19

  Online published: 2024-09-13

Fold

Abstract

Mantle cell lymphoma （MCL） is a rare B-cell non-Hodgkin's lymphoma characterized by clinical and pathological features encompassing both indolent and aggressive subtypes. Significant progress has been made in the past decade regarding the development of novel therapeutic options for MCL. Particularly， Bruton's tyrosine kinase inhibitor （BTKi） has exhibited remarkable efficacy in treating patients with MCL by specifically targeting the BTK protein， thereby inhibiting B-cell proliferation and inducing potent anti-tumor effects. Currently， global approval has been granted to five BTK inhibitors for MCL treatment， including the first-generation Ibrutinib， second-generation Acalabrutinib， Zanubrutinib， Orelabrutinib， as well as the non-covalent BTKi Pirtobrutinib. This review provides a comprehensive summary of findings from clinical trials investigating the use of BTKi in MCL treatment and offers valuable insights for clinical practice.

Key words： BTK inhibitor; relapsed; refractory; mantle cell lymphoma; targeted therapy

Cite this article

Sishi XU , Peipei. YE . Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma[J]. The Journal of Practical Medicine, 2024 , 40(17) : 2363 -2368 . DOI: 10.3969/j.issn.1006-5725.2024.17.002

References

1 ARMITAGE J O， LONGO D L. Mantle-Cell Lymphoma［J］. N Engl J Med， 2022，386（26）：2495-2506. doi:10.1056/nejmra2202672
2 MCCULLOCH R， VISCO C， EYRE T A，et al. Efficacy of R-BAC in relapsed， refractory mantle cell lymphoma post BTK inhibitor therapy［J］. Br J Haematol，2020，189（4）：684-688. doi:10.1111/bjh.16416
3 LU T， ZHANG J， MCCRACKEN J M，et al. Recent advances in genomics and therapeutics in mantle cell lymphoma［J］. Cancer Treat Rev， 2024， （122）：102651. doi:10.1016/j.ctrv.2023.102651
4 董佳艺，邵丽娟，郑柱，等. 嵌合抗原受体T细胞联合分子靶向药治疗实体瘤研究进展［J］. 实用医学杂志，2023，39（7）：798-803.
5 ESTUPI?áN H Y， WANG Q， BERGL?F A，et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib，ibrutinib and zanubrutinib［J］. Leukemia，2021，35（5）：1317-1329. doi:10.1038/s41375-021-01123-6
6 KEAM S J. Pirtobrutinib： First Approval［J］. Drugs，2023，83（6）：547-553. doi:10.1007/s40265-023-01860-1
7 RULE S， DREYLING M，GOY A，et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib：a pooled analysis from three open‐label studies［J］. Br J Haematol，2017，179（3）：430-438. doi:10.1111/bjh.14870
8 DREYLING M， JURCZAK W， JERKEMAN M，et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma：an international，randomised，open-label，phase 3 study［J］. Lancet，2016，387（10020）：770-778. doi:10.1016/s0140-6736(15)00667-4
9 ESTUPI?áN H Y， BERGL?F A， ZAIN R，et al. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects［J］. Front Cell Dev Biol，2021，9：630942. doi:10.3389/fcell.2021.630942
10 JERKEMAN M， ESKELUND C W， HUTCHINGS M，et al. Ibrutinib， lenalidomide，and rituximab in relapsed or refractory mantle cell lymphoma （PHILEMON）： A multicentre，open-label，single-arm，phase 2 trial［J］. Lancet Haematol，2018，5（3）：e109-e116. doi:10.1016/s2352-3026(18)30018-8
11 TAM C S， ANDERSON M A， POTT C，et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma［J］. N Engl J Med，2018， 378（13）：1211-1223. doi:10.1056/nejmoa1715519
12 LE GOUILL S， MORSCHHAUSER F， CHIRON D，et al. Ibrutinib， obinutuzumab，and venetoclax in relapsed and untreated patients with mantle cell lymphoma： A phase 1/2 trial［J］. Blood，2021，137（7）：877-887. doi:10.1182/blood.2020008727
13 DAVIDS M S， KIM H T， NICOTRA A，et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma： a multicentre phase 1-1b study［J］. Lancet Haematol，2019，6（1）：e38-e47.
14 MARTIN P， BARTLETT N L， BLUM K A，et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma［J］. Blood， 2019，133（11）：1201-1204. doi:10.1182/blood.2019002741
15 WANG M， RAMCHANDREN R， CHEN R，et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma：the safety run-in of the phase 3 SYMPATICO study［J］. J Hematol Oncol， 2021， 14（1）：179. doi:10.1186/s13045-021-01188-x
16 TIVEY A， SHOTTON R， EYRE T A，et al. Ibrutinib as first line therapy for mantle cell lymphoma：A multicentre，real-world UK study［J］. Blood Adv， 2024，8（5）：1209-1219.
17 WANG M L， JURCZAK W， JERKEMAN M，et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma［J］. N Engl J Med， 2022，386（26）：2482-2494. doi:10.1056/nejmoa2201817
18 Update on IMBRUVICA? （ibrutinib） U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications［EB ］（2023-04-06） ［2024-02-03］ . .
19 DREYLING M， DOORDUIJN J K， GINE E，et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma （TRIANGLE）： a three-arm，randomised， open-label，phase 3 superiority trial of the European Mantle Cell Lymphoma Network［J］. Lancet，2024，403（10441）：2293-2306.
20 IZUTSU K， ANDO K， ENNISHI D，et al. Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies：A Japanese phase I study［J］. Cancer Sci， 2021，112（6）：2405-2415. doi:10.1111/cas.14886
21 LE GOUILL S， D?UGOSZ-DANECKA M， RULE S，et al. Final results and overall survival data from a phase Ⅱ study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma，including those with poor prognostic factors［J］. Haematologica， 2024，109（1）：343-350.
22 KIM A I， ARMAND P， REDD R A，et al. Phase I Safety and Preliminary Efficacy of Acalabrutinib，Venetoclax，and Obinutuzumab （AVO） in Patients with Relapsed/Refractory Mantle Cell Lymphoma［J］. Blood， 2023，142（）：3031. doi:10.1182/blood-2023-173103
23 BAIRD J H， DEL REAL M M， SONG J Y，et al. CD19-Directed CAR T-Cells （CD19-CAR） Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory （r/r） Mantle Cell Lymphoma （MCL）［J］. Blood，2023，142（）：4840. doi:10.1182/blood-2023-182456
24 POH C， CHOW V A， LYNCH R C，et al. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma：A Phase Ⅰ/ⅡStudy of Safety， Efficacy and Immune Correlative Analysis［J］.Blood，2023，142 （）：2129.
25 VILLA D， LAROUCHE J F， CHEUNG M C，et al. Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma： The Rectangle Trial［J］. Blood，2023，142 （）：3042. doi:10.1182/blood-2023-179375
26 HAWKES E A， LEE S T， CHURILOV L，et al. A Window Study of Acalabrutinib & Rituximab， Followed By Chemotherapy & Autograft （ASCT） in Fit Patients with Treatment Naive Mantle Cell Lymphoma （MCL）：First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 “Wamm” Trial［J］. Blood，2023，142（）：735. doi:10.1182/blood-2023-178403
27 WANG M， ROBAK T， MADDOCKS K J，et al. Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Na?ve （TN） Mantle Cell Lymphoma （MCL）［J］.Blood，2021，138（）： 2416. doi:10.1182/blood-2021-146615
28 HAWKES E A， FLETCHER R， WOOD A，et al. Traverse： A Phase 2， Open-Label， Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma［J］. Blood，2023， 142（）：3054.
29 ZHOU K， ZOU D， ZHOU J，et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma： a pooled analysis of two clinical trials［J］. J Hematol Oncol，2021，14（1）：167. doi:10.1186/s13045-021-01174-3
30 KUMAR A， SOUMERAI J， ABRAMSON J S，et al. A Multicenter Phase 2 Trial of Zanubrutinib，Obinutuzumab，and Venetoclax （BOVen） in Patients with Treatment-Naive， TP53-Mutant Mantle Cell Lymphoma［J］. Blood，2023，142（）：738. doi:10.1182/blood-2023-180069
31 HILL H A， QI X， JAIN P，et al. Genetic mutations and features of mantle cell lymphoma： a systematic review and meta-analysis［J］. Blood Adv， 2020，4（13）：2927-2938. doi:10.1182/bloodadvances.2019001350
32 DENG L J， ZHOU K S， LIU L H，et al. Orelabrutinib for the treatment of relapsed or refractory MCL：a phase 1/2，open-label， multicenter，single-arm study［J］. Blood Adv， 2023，7（16）：4349-4357. doi:10.1182/bloodadvances.2022009168
33 DHILLON S. Orelabrutinib： First Approval［J］. Drugs， 2021，81（4）： 503-507.
34 ZHANG H， SU L， LIU L，et al. A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab（OLR） in Patients with Untreated Mantle Cell Lymphoma（MCL） in China（POLARIS Study）： Preliminary Analysis on Efficacy，Safety，Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses［J］. Blood， 2023，142（）：736. doi:10.1182/blood-2023-178509
35 GOMEZ E B， EBATA K， RANDERIA H S，et al. Preclinical characterization of pirtobrutinib， a highly selective，noncovalent（reversible） BTK inhibitor［J］. Blood， 2023，142（1）：62-72.
36 MATO A R， SHAH N N， JURCZAK W，et al. Pirtobrutinib in relapsed or refractory B-cell malignancies（BRUIN）：a phase 1/2 study［J］. Lancet， 2021，397（10277）：892-901. doi:10.1016/s0140-6736(21)00224-5
37 COHEN J B， SHAH N N， JURCZAK W，et al. Pirtobrutinib in Relapsed/Refractory（R/R） Mantle Cell Lymphoma（MCL） Patients with Prior cBTKi：Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study［J］. Blood，2023，142（）：981. doi:10.1182/blood-2023-181627
38 EYRE T A， SHAH N N， DREYLING M，et al. BRUIN MCL-321：phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma［J］. Future Oncol， 2022， 18（36）：3961-3969.
39 RULE S A， CARTRON G， FEGAN C，et al. Long-term follow-up of patients with mantle cell lymphoma（MCL） treated with the selective Bruton′s tyrosine kinase inhibitor tirabrutinib（GS/ONO-4059）［J］. Leukemia， 2020，34（5）：1458-1461. doi:10.1038/s41375-019-0658-7
40 ELGAMAL O A， MEHMOOD A， JEON J Y，et al. Preclinical efficacy for a novel tyrosine kinase inhibitor， ArQule 531 against acute myeloid leukemia［J］. J Hematol Oncol， 2020，13（1）：8. doi:10.1186/s13045-019-0821-7
41 WOYACH J A， STEPHENS D M， FLINN I W，et al. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma［J］. Cancer Discov，2024，14（1）：66-75. doi:10.1158/2159-8290.cd-23-0670
42 MATO A R， WIERDA W G， AI W Z，et al. NX-2127-001， a First-in-Human Trial of NX-2127， a Bruton′s Tyrosine Kinase-Targeted Protein Degrader， in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies［J］. Blood，2022，140（）： 2329-2332.
Options
Outlines

/

〈 〉